Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GS 8824

Next Previous
Drug Profile

GS 8824

Alternative Names: GS-8824; TUB-040; TUB-40

Latest Information Update: 14 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tubulis
  • Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 09 Sep 2026 Tubulis plans a phase II trial for Non-small cell lung cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion) (NCT07806773)
  • 05 Aug 2026 Tubulis plans a phase I/II NAPISTAR 1-03 trial for Endometrial-cancer (Late-stage disease, Recurrent, Second-line therapy or greater) in US in October 2026 (IV) (NCT07743541)
  • 02 Jun 2026 Efficacy and adverse events data from a phase I/II trial in Ovarian cancer and Non-small cell lung cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top